Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.
Abigail R. Aronson, Brigham and Women's Hospital, Boston, Massachusetts

Main Body of the Abstract
BACKGROUND: From clinical experience and clinical trials it is apparent that patients with ATTR cardiac amyloidosis (ATTR-CA) are being diagnosed earlier and with less severe disease, than those seen a decade ago. Yet, this remains a disease of aging, hence, frailty is an important consideration in ATTR-CM. Frailty adversely affects outcome in many diseases. We therefore sought to determine the proportion of patients in a contemporary population referred to an amyloidosis program who meet criteria for clinical frailty.
METHODS: 116 unselected patients with proven ATTR-CM underwent the Short Physical Performance Battery (SPPB) and standard clinical evaluations. The SPPB consists of a brief series of physical tests assessing balance, gait speed and unassisted standing from a chair, and is scored from 0-12 with a score of 8 or lower indicative of frailty.
RESULTS: 45 patients (38.8%) were found to have a SPPB score ≤8, indicative of frailty. Those with a low SPPB had higher rates of atrial fibrillation/flutter or a paced rhythm (12/71 v 22/45. P=0.02), and higher NT-proBNP (median 1170 (560-2459) pg/ml v. 1977 (970-3197) pg/ml. P =0.024). Global longitudinal strain, a marker of cardiac function, did not differ between groups.
CONCLUSION: In a population of patients with ATTR amyloidosis, frailty remains a substantial problem among a large minority of patients. We strongly recommend its assessment in all ATTR-CA. This can be easily achieved, in less than 10 minutes, using the easy-to-learn and simple to perform, SPPB score.

**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Abigail R. Aronson, Brigham and Women's Hospital, Boston, Massachusetts

**Main Body of the Abstract**
**BACKGROUND:** From clinical experience and clinical trials it is apparent that patients with ATTR cardiac amyloidosis (ATTR-CA) are being diagnosed earlier and with less severe disease, than those seen a decade ago. Yet, this remains a disease of aging, hence, frailty is an important consideration in ATTR-CM. Frailty adversely affects outcome in many diseases. We therefore sought to determine the proportion of patients in a contemporary population referred to an amyloidosis program who meet criteria for clinical frailty.
**METHODS:** 116 unselected patients with proven ATTR-CM underwent the Short Physical Performance Battery (SPPB) and standard clinical evaluations. The SPPB consists of a brief series of physical tests assessing balance, gait speed and unassisted standing from a chair, and is scored from 0-12 with a score of 8 or lower indicative of frailty.
**RESULTS:** 45 patients (38.8%) were found to have a SPPB score ≤8, indicative of frailty. Those with a low SPPB had higher rates of atrial fibrillation/flutter or a paced rhythm (12/71 v 22/45. P=0.02), and higher NT-proBNP (median 1170 (560-2459) pg/ml v. 1977 (970-3197) pg/ml. P =0.024). Global longitudinal strain, a marker of cardiac function, did not differ between groups.
**CONCLUSION:** In a population of patients with ATTR amyloidosis, frailty remains a substantial problem among a large minority of patients. We strongly recommend its assessment in all ATTR-CA. This can be easily achieved, in less than 10 minutes, using the easy-to-learn and simple to perform, SPPB score.

Prevalence of frailty in a contemporary population of ATTR cardiac amyloidosis PC80 (#562)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.